[go: up one dir, main page]

MX2009008923A - Compuestos y metodos para modular receptores acoplados por proteina g. - Google Patents

Compuestos y metodos para modular receptores acoplados por proteina g.

Info

Publication number
MX2009008923A
MX2009008923A MX2009008923A MX2009008923A MX2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A MX 2009008923 A MX2009008923 A MX 2009008923A
Authority
MX
Mexico
Prior art keywords
compounds
modulating
protein
methods
coupled receptors
Prior art date
Application number
MX2009008923A
Other languages
English (en)
Inventor
Robert Epple
Mihai Azimioara
Ross Russo
Christopher Cow
Victor Nikulin
Gerald Lelais
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MX2009008923A publication Critical patent/MX2009008923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona compuestos y composiciones farmacéuticas de los mismos, que son útiles para modular el receptor 20 acoplado por proteína G (GPR20), y métodos para utilizar dichos compuestos para tratar, aminorar o prevenir una condición asociada con GPR20 anormal o desregulado.
MX2009008923A 2007-02-22 2008-01-08 Compuestos y metodos para modular receptores acoplados por proteina g. MX2009008923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89117807P 2007-02-22 2007-02-22
PCT/US2008/050507 WO2008103501A1 (en) 2007-02-22 2008-01-08 Compounds and methods for modulating g protein-coupled receptors

Publications (1)

Publication Number Publication Date
MX2009008923A true MX2009008923A (es) 2009-08-28

Family

ID=39522201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008923A MX2009008923A (es) 2007-02-22 2008-01-08 Compuestos y metodos para modular receptores acoplados por proteina g.

Country Status (11)

Country Link
US (1) US8394841B2 (es)
EP (1) EP2125758A1 (es)
JP (1) JP5175866B2 (es)
KR (1) KR20090113901A (es)
CN (1) CN101646660A (es)
AU (1) AU2008218951B2 (es)
BR (1) BRPI0807552A2 (es)
CA (1) CA2677706A1 (es)
EA (1) EA200901099A1 (es)
MX (1) MX2009008923A (es)
WO (1) WO2008103501A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362050B2 (en) * 2008-06-24 2013-01-29 Irm Llc Compounds and methods for modulating G protein-coupled receptors
CN102186825A (zh) * 2008-10-21 2011-09-14 麦它波莱克斯股份有限公司 芳基gpr120受体激动剂和其用途
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
AU2010221980A1 (en) 2009-03-11 2011-10-13 Msd K.K. Novel isoindolin-1-one derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105008345A (zh) * 2013-03-14 2015-10-28 詹森药业有限公司 可用作gpr120的激动剂的双环吡咯衍生物
ES2690145T3 (es) 2013-03-14 2018-11-19 Janssen Pharmaceutica Nv Agonistas de GPR120 para el tratamiento de diabetes de tipo 2
KR102422559B1 (ko) 2013-03-14 2022-07-18 얀센 파마슈티카 엔.브이. Gpr120의 작용제로서 유용한 벤조 융합된 헤테로사이클릭 유도체
WO2015125085A1 (en) 2014-02-19 2015-08-27 Piramal Enterprises Limited Compounds for use as gpr120 agonists
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
US8912227B1 (en) 2014-03-07 2014-12-16 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
EP3172185B1 (en) 2014-07-25 2020-03-04 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
EP3191463B1 (en) 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
WO2016105118A2 (ko) * 2014-12-24 2016-06-30 주식회사 엘지생명과학 Gpr120 효능제로서의 바이아릴 유도체
CA2974060C (en) 2015-02-05 2022-08-30 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
CN105477451A (zh) * 2016-01-08 2016-04-13 董仲璧 一种治疗癌症及癌症疼痛、发热的中药组合物
KR102537985B1 (ko) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Gpr120 조정제로서 유용한 단환형 화합물
EP3509588B1 (en) * 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
CN108329306A (zh) * 2017-07-09 2018-07-27 曹艳 一种用于治疗艾滋病药物的制备方法
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
CN113956213A (zh) * 2021-11-19 2022-01-21 烟台药物研究所 一类2，4-二取代噻唑结构的PPARα/δ双重激动剂及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU510758B2 (en) * 1976-01-19 1980-07-10 The Dow Chemical Company P-benzylaminobenzoic acids
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
JP3466273B2 (ja) * 1993-06-11 2003-11-10 武田薬品工業株式会社 テトラゾール誘導体、その製造法およびそれを含んでなる医薬
CN1107059C (zh) 1994-10-14 2003-04-30 山之内制药株式会社 吡咯衍生物
GB2328975A (en) * 1997-09-03 1999-03-10 Ford Global Tech Inc Combustion engine with internal EGR
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
WO2005111600A1 (en) 2004-05-04 2005-11-24 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method of analysis using chromatographic pre-separation
PE20060362A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de oxazol como moduladores de ppar
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
CN101304983A (zh) * 2005-11-07 2008-11-12 Irm责任有限公司 作为ppar调节剂的化合物和组合物

Also Published As

Publication number Publication date
US20100035944A1 (en) 2010-02-11
CA2677706A1 (en) 2008-08-28
KR20090113901A (ko) 2009-11-02
EA200901099A1 (ru) 2010-04-30
AU2008218951A1 (en) 2008-08-28
BRPI0807552A2 (pt) 2014-07-01
CN101646660A (zh) 2010-02-10
JP5175866B2 (ja) 2013-04-03
JP2010519306A (ja) 2010-06-03
WO2008103501A1 (en) 2008-08-28
AU2008218951B2 (en) 2011-11-17
US8394841B2 (en) 2013-03-12
EP2125758A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
MX2009008923A (es) Compuestos y metodos para modular receptores acoplados por proteina g.
MX2009008921A (es) Derivados de tiazole en la forma de moduladores de receptores acoplados por proteina g.
WO2008033408A3 (en) Methods for identifying compounds that modulate cell signaling and methods employing such compounds
TNSN07264A1 (en) Organic compounds
MX2009005461A (es) N-oxidos de analogos de 4,5-epoxi-morfinano.
ZA200900885B (en) Compounds which modulate the CB2 receptor
WO2009061652A8 (en) Compounds which modulate the cb2 receptor
WO2008042571A3 (en) Substituted indole compounds
MX2009003611A (es) Compuestos antagonistas del receptor de glucagon, composiciones que contienen dichos compuestos y metodos de uso.
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX343625B (es) Composiciones plagicidas.
SG169353A1 (en) Tamper resistant dosage forms
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
MX2010002028A (es) Metodos y composiciones para modular celulas t.
TN2010000269A1 (en) 4-phenylpyrane-3,5-diones, 4-phenylthiopyrane-3,5-diones and 2- phenylcyclohexane -1,3,5 - triones as herbicides
EP2179598A4 (en) SECURE LOCALIZATION FOR 802.11 NETWORKS WITH FINE GRANULARITY
WO2009016253A3 (en) Cyanomethyl substituted n-acyl tryptamines
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010147792A3 (en) Compounds which selectively modulate the cb2 receptor
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TN2010000062A1 (en) Pyrrolidin -2-one derivatives as androgen receptor modulator
IN2012DN02876A (es)
MX2009007284A (es) Cd200 y su receptor, cd200r, modulan la masa osea por medio de la diferenciacion de osteoclastos.
MY178894A (en) Therapeutic compositions containing macitentan
TW200800967A (en) Benzimidazole thiophene compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal